Carcinoid valve disease

被引：23
作者：
Askew J.W. [1 ]
Connolly H.M. [1 ]
机构：
[1] Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, Gonda 6
来源：
Current Treatment Options in Cardiovascular Medicine | 2013年 / 15卷 / 5期
关键词：
Carcinoid; Carcinoid heart disease; Carcinoid syndrome; Carcinoid tumors; Carcinoid valve disease; Pulmonary regurgitation; Pulmonary stenosis; Serotonin; Somatostatin; Tricuspid regurgitation; Valve surgery; Valves; Valvular heart disease;
D O I：
10.1007/s11936-013-0265-2
中图分类号：
学科分类号：
摘要：
Opinion statement: Carcinoid is a rare neuroendocrine tumor that typically originates in the gastrointestinal tract and can result in a constellation of symptoms, mediated by vasoactive substances, referred to as carcinoid syndrome. Carcinoid valve and heart disease is characterized by the plaque-like, endocardial fibrous tissue deposits, primarily affecting the right heart endocardium and valves, which result as a consequence of the disease process. Potential mechanisms for the carcinoid valve disease include the complex role of excess serotonin and its interaction with serotonin receptors and transporters. Carcinoid valve and heart disease is a frequent occurrence in patients with carcinoid syndrome and is accountable for substantial morbidity and mortality. Cardiac surgery remains the most effective treatment option for carcinoid valve disease and a multidisciplinary approach at an experienced center is recommended for patients with metastatic carcinoid and carcinoid heart disease. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：544 / 555
页数：11
相关论文
共 57 条
  • [31] Lee K.J., Connolly H.M., Pellikka P.A., Carcinoid pulmonary valvulopathy evaluated by real-time 3-dimensional transthoracic echocardiography, J Am Soc Echocardiogr, 21, (2008)
  • [32] Dumaswala B., Bicer E.I., Dumaswala K., Et al., Live-real time three-dimensional transthoracic echocardiographic assessment of the involvement of cardiac valves and chambers in carcinoid disease, Echocardiography., 29, pp. 751-756, (2012)
  • [33] Kubota A., Yamada Y., Kagimoto S., Et al., Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors, J Clin Invest, 93, pp. 1321-1325, (1994)
  • [34] Rinke A., Muller H.-H., Schade-Brittinger C., Et al., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group, J Clin Oncol, 27, pp. 4656-4663, (2009)
  • [35] Oberg K., Biotherapies for GEP-NETs. Best practice & research clinical, Gastroenterology, 26, pp. 833-841, (2012)
  • [36] Oberg K., Norheim I., Lundqvist G., Et al., Cytotoxic treatment in patients with malignant carcinoid tumors: Response to streptozocin - Alone or in combination with 5-FU, Acta Oncol, 26, pp. 429-432, (1987)
  • [37] Ansell S.M., Pitot H.C., Burch P.A., Et al., A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors, Cancer, 91, pp. 1543-1548, (2001)
  • [38] Ritzel U., Leonhardt U., Stockmann F., Et al., Treatment of metastasized midgut carcinoids with decarbazine, Am J Gastroenterol, 90, pp. 627-631, (1995)
  • [39] Bushnell D.L., O'Dorisio T.M., O'Dorisio M.S., Et al., 90Y-edotreotide for metastatic carcinoid refractory to octreotide, J Clin Oncol, 28, pp. 1652-1659, (2010)
  • [40] Lillegard J.B., Fisher J.E., McKenzie T.J., Et al., Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: Does valve replacement permit safe hepatic resection?, J Am Coll Surg, 213, pp. 130-136, (2011)
123456